X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
aged (19) 19
male (18) 18
female (17) 17
index medicus (17) 17
middle aged (16) 16
pyrazoles - therapeutic use (13) 13
pyrimidines - therapeutic use (13) 13
adult (12) 12
aged, 80 and over (11) 11
leukemia, lymphocytic, chronic, b-cell - drug therapy (11) 11
lymphomas (11) 11
pyrazoles - adverse effects (11) 11
pyrimidines - adverse effects (11) 11
hematology (10) 10
leukemia (10) 10
pci-32765 (9) 9
rituximab (9) 9
survival (9) 9
abridged index medicus (8) 8
human necessities (8) 8
hygiene (8) 8
lymphoma (8) 8
medical or veterinary science (8) 8
patients (8) 8
therapy (8) 8
article (7) 7
care and treatment (7) 7
cll (7) 7
disease-free survival (7) 7
fludarabine (7) 7
ibrutinib (7) 7
preparations for medical, dental, or toilet purposes (7) 7
protein-tyrosine kinases - antagonists & inhibitors (7) 7
recurrence (7) 7
tyrosine (7) 7
cancer (6) 6
chemotherapy (6) 6
chronic lymphocytic-leukemia (6) 6
drug therapy (6) 6
leukemia, lymphocytic, chronic, b-cell - mortality (6) 6
survival rate (6) 6
analysis (5) 5
antineoplastic agents - therapeutic use (5) 5
btk (5) 5
calculating (5) 5
chronic lymphatic leukemia (5) 5
chronic lymphocytic leukemia (5) 5
clinical trials (5) 5
computing (5) 5
counting (5) 5
data processing systems or methods, specially adapted foradministrative, commercial, financial, managerial, supervisoryor forecasting purposes (5) 5
medicine, general & internal (5) 5
mutation (5) 5
neutropenia (5) 5
oncology (5) 5
open-label (5) 5
physics (5) 5
protein kinase inhibitors - therapeutic use (5) 5
protein-tyrosine kinase (5) 5
systems or methods specially adapted for administrative,commercial, financial, managerial, supervisory or forecastingpurposes, not otherwise provided for (5) 5
treatment outcome (5) 5
bruton's tyrosine kinase (4) 4
chlorambucil (4) 4
cyclophosphamide (4) 4
diarrhea (4) 4
fatigue (4) 4
follow-up studies (4) 4
guidelines (4) 4
hematology, oncology and palliative medicine (4) 4
hemic and lymphatic diseases (4) 4
kinases (4) 4
product development (4) 4
protein kinase inhibitors - adverse effects (4) 4
pyrazoles - administration & dosage (4) 4
pyrazoles - pharmacology (4) 4
pyrimidines - administration & dosage (4) 4
pyrimidines - pharmacology (4) 4
thrombocytopenia (4) 4
variant (4) 4
activation (3) 3
antigen receptor (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - adverse effects (3) 3
bruton tyrosine kinase (3) 3
chromosome deletion (3) 3
clinical trials and observations (3) 3
clonal deletion (3) 3
cohort studies (3) 3
diagnosis (3) 3
dose-response relationship, drug (3) 3
follow-up (3) 3
hemoglobin (3) 3
inhibitor (3) 3
lymphatic leukemia (3) 3
lymphocytes b (3) 3
lymphocytosis (3) 3
lymphoma, mantle-cell - drug therapy (3) 3
mantle cell lymphoma (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 1, pp. 32 - 42
Ibrutinib inhibits Bruton's tyrosine kinase, a component of normal B-cell activation pathways. Ibrutinib produced responses in 71% of patients with refractory... 
MEDICINE, GENERAL & INTERNAL | BRUTONS TYROSINE KINASE | ACTIVATION | RITUXIMAB | B-CELL MALIGNANCIES | PCI-32765 | SURVIVAL SIGNALS | KAPPA-B | INHIBITOR | ANTIGEN RECEPTOR | FLUDARABINE | Recurrence | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Treatment Outcome | Pyrimidines - pharmacology | Remission Induction | Disease-Free Survival | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Chronic lymphocytic leukemia | Care and treatment | Product development | Antineoplastic agents | Tyrosine | Cell proliferation | Pharmacodynamics | Chronic lymphatic leukemia | Cell survival | Risk groups | Leukemia | Diarrhea | Fatigue | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Risk factors | Cell adhesion & migration | Clonal deletion | Lymphocytes B | Respiratory tract diseases | Lymphomas | Pharmacokinetics | Lymphocytosis | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 6, pp. 507 - 516
Journal Article
Journal Article
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 15, pp. 1430 - 1440
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2015, Volume 21, Issue 8, pp. 922 - 926
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2425 - 2437
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 213 - 223
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2019, Volume 20, Issue 1, pp. 43 - 56
Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments... 
CLL | OFATUMUMAB | ONCOLOGY | CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | GUIDELINES | FOLLOW-UP | FLUDARABINE | EXPRESSION | PROGRESSION | Antimitotic agents | Antineoplastic agents | Product development
Journal Article